Aelix Therapeutics, a company that develops drugs and specializes in discovering and creating immunotherapies to treat HIV infections, recently stated that it has finished its Series A round of funds for a new HIV vaccine.
This round of funds, which amounts to $12.7 million, was used to create proof of concept studies testing a lead candidate HTI immunogen. This immunogen may be a potential therapeutic vaccine to protect people from HIV infections.
"We believe that Aelix's innovative approach, based on a disruptive design of a T-cell immunogen that is able to elicit a strong, broad and focused response against HIV, has the potential to radically transform the treatment of HIV infection, still one of the largest health problems in the world," Karen Wagner from Ysios Capital said. "We were impressed by the science and the preclinical data supporting the HTI immunogen. We believe that this may indeed change the future of how HIV infection is treated and also help to improve the health of millions of people globally."
The round of funds was under the leadership of Ysios Capital, which is an investment fund based in Spain. Fundraising included new investors, such as Caiza Capital Risc, Johnson & Johnson Innovation – JJDC Inc., and others.
With the funds, the company can add four new board members to its leadership team.
"We are delighted to have closed such an important equity round,” Christian Brander, chief scientific officer and co-founder of Aelix Therapeutics, said. “The investment syndicate includes many complementary parties, specifically the corporate investors from pharmaceutical companies with expertise in virology and vaccine development. We also look forward to working with the research community to test this concept.”